Imperial Innovations

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, founded in 2014. It focuses on the research and development of innovative therapies for respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company aims to create disease-modifying therapies that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increased susceptibility to lung infections. By developing these novel treatments, Enterprise Therapeutics seeks to enhance the quality of life for patients suffering from these chronic respiratory conditions.

Resolver is an independent online resolution service that connects consumers directly with businesses to address customer service issues efficiently. The platform facilitates communication and provides a streamlined process for resolving disputes, ensuring that consumers can effectively voice their concerns while businesses can retain their customers. Resolver offers a fully online, end-to-end arbitration and dispute resolution system, which is both fast and cost-effective. Additionally, the platform delivers value-added services to businesses by enhancing the issue-resolution process and providing real-time consumer feedback insights through advanced AI technology. This comprehensive approach allows consumers to receive guidance throughout the complaint process, while enterprises can transform their handling of customer complaints.

ThisWay operates an online recruitment platform that leverages advanced machine learning and blockchain technology to enhance talent acquisition services. Its flagship solution, AI4Jobs, significantly improves the efficiency and accuracy of candidate sourcing, offering a matched and scored list of qualified candidates within minutes. This approach not only streamlines the hiring process but also promotes diversity and inclusion, ultimately optimizing return on investment for businesses. The platform is designed for ease of use, requiring no integration while providing all necessary features to facilitate effective job searches for individuals and organizations alike.

Concirrus is a prominent Insurtech company focused on enhancing risk selection, pricing, and claims processes through advanced data analytics, artificial intelligence, and machine learning. Its intelligence platform, Quest, provides organizations with the tools to improve loss ratios, lower operational costs, and facilitate larger deal sizes and new trading relationships. By analyzing customer behavior and delivering extensive data insights, Concirrus empowers underwriting teams to make swift, data-driven decisions. The company serves over 20 industry leaders, including Marsh, Beazley, and Hiscox, who rely on its technology for informed risk management. Headquartered in London, Concirrus boasts a team of around 100 experts with deep expertise in data analytics and a comprehensive understanding of the global insurance landscape, particularly in marine and automotive commercial insurance markets.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

Oxular Limited is a clinical-stage company based in Oxford, United Kingdom, focused on developing innovative retinal treatments to address various retinal diseases. Founded in 2014, the company specializes in tissue-specific drug delivery technology aimed at improving the effectiveness of treatments for conditions such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and cystoid macular edema. By targeting specific areas within the eye, Oxular seeks to enhance therapeutic outcomes while minimizing side effects and reducing the frequency of treatments, thereby offering patients effective and life-changing solutions for their unmet medical needs.

Abingdon Health is a technology-enabled company specializing in lateral flow diagnostics, focused on developing, manufacturing, and marketing medical diagnostic solutions globally. Founded in 2008 and based in York, United Kingdom, the company offers a range of products, including the AbC-19 Rapid Test for COVID-19 neutralizing antibodies, as well as tests for self-test HIV, equine infections, and human fertility. Abingdon Health also provides services in lateral flow test development, manufacturing, and reader customization. Its business operations are divided into three main segments: Contract Development, which involves development work for third parties; Contract Manufacturing, encompassing both development and manufacturing activities; and Product Sales, which includes sales of various diagnostic products. The majority of the company's revenue is generated from its Contract Development segment.

Econic Technologies Ltd. is a UK-based chemical technology company that specializes in developing innovative processes for producing polymers and polyurethanes using carbon dioxide and epoxides. Founded in 2011 and located in Macclesfield, the company focuses on transforming waste CO2 into valuable materials through advanced catalyst chemistry. Its product offerings include polycarbonates and polycarbonate polyols, which find applications in various sectors such as mattresses, home insulation, footwear, packaging, and construction. The company’s technology not only reduces dependence on fossil fuels but also aims to provide environmental benefits by mitigating greenhouse gas emissions. With a team of skilled scientists and engineers operating from a state-of-the-art facility at Alderley Park, Econic Technologies is committed to advancing sustainable practices in the plastics industry while fostering economic growth.

Targeting pathways that modify RNA to deliver novel cancer therapeutics.

Featurespace is a leader in enterprise financial crime prevention, specializing in fraud detection and anti-money laundering solutions. The company has developed innovative technologies, including Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, which are incorporated into its ARIC platform. This real-time machine learning software assesses risk and monitors customer data across more than 180 countries to identify fraudulent activities and suspicious behavior promptly. The ARIC Risk Hub utilizes advanced anomaly detection methods, allowing financial institutions to automatically recognize potential threats and respond to them effectively. Over 30 major global financial institutions, including well-known names such as HSBC and NatWest, leverage Featurespace’s solutions to safeguard their operations and enhance customer satisfaction while minimizing fraud-related costs.

Inflowmatix is a spin-out company from the InfraSense Labs at the Department of Civil and Environmental Engineering of Imperial College London. Inflowmatix builds upon the unique cross-disciplinary expertise from sensing to advanced modelling and optimization and the active research collaborations with water utilities and IT system integrators. Inflowmatix creates innovative and customer tailored solutions for the steady-state, resilient and energy efficient operation of water supply networks by continuously monitoring and analyzing the fluid dynamics in complex networks. This allows operators to continuously gain unique insight and proactively optimize the dynamic network performance in order to extend the service life of infrastructure assets. Our expertise in modelling the steady and unsteady-state hydraulics of water distribution networks, combined with knowledge and experience in the design and implementation of embedded electronic systems, yield compelling returns on investment for our customers. Many cities in the world face the problem of ageing infrastructure, increasing population demand and climate change. This combined with increasing regulatory and financial pressure means water utilities are actively seeking novel, integrated and optimized operational strategies for managing leakage, demand and energy efficiency in order to deliver high-quality of service to customers within cost constraints. Water companies and operators are facing unparalleled challenges to meet increasing demand with limited water and financial resources. By successfully applying the technologies and analytics developed by Inflowmatix to water supply networks, we significantly improve the management of leakage, demand, energy and operational incidents, thus providing multiple operational benefits for network operators.

Nexeon Limited is a developer and manufacturer of advanced silicon-based anode materials for rechargeable lithium-ion batteries. Founded in 2006 and headquartered in Abingdon, United Kingdom, with an additional office in Yokohama, Japan, the company focuses on creating innovative battery materials that enhance energy density and capacity. These improvements allow for the production of lighter, more powerful batteries that can support a variety of applications, including consumer electronics, electric vehicles, sustainable energy, aerospace, medical, and defense industries. By enabling longer battery life and faster charging times, Nexeon's technology plays a crucial role in advancing sustainable energy solutions and supporting the transition to a net-zero environment. The company boasts a skilled technical team with diverse expertise to drive its research and development efforts.

Oxular Limited is a clinical-stage company based in Oxford, United Kingdom, focused on developing innovative retinal treatments to address various retinal diseases. Founded in 2014, the company specializes in tissue-specific drug delivery technology aimed at improving the effectiveness of treatments for conditions such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and cystoid macular edema. By targeting specific areas within the eye, Oxular seeks to enhance therapeutic outcomes while minimizing side effects and reducing the frequency of treatments, thereby offering patients effective and life-changing solutions for their unmet medical needs.

Aqdot Limited, founded in 2012 and based in Cambridge, United Kingdom, specializes in manufacturing smart microcapsules through innovative fabrication technology. Its unique approach combines emulsion technology and supramolecular chemistry to simplify the microencapsulation process using a one-step shrink-wrap method. This technology is energy- and raw material-efficient, contributing to reduced energy consumption and waste. Aqdot's microcapsules have versatile applications across various industries, including home care, beauty, pet care, food, and agrochemicals. The encapsulation technology enables the protection and controlled release of active ingredients, making it suitable for products like laundry detergents, fertilizers, and odor-capturing technologies. With a focus on customization, Aqdot serves a multi-billion-dollar market, addressing the growing demand for effective and sustainable encapsulation solutions.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

SAM Labs provides everything you need to deliver the most engaging STEAM learning experience to your classroom. It seamlessly connects software and hardware with lesson plans that cover a wide variety of subjects, making learning about coding accessible, experimental, interactive and fun. SAM Labs kits are bursting with wireless electronic blocks that each have a personality of their own. From lights to motors to sliders to buzzers, every Bluetooth-enabled block can connect to the others via the app to do something different. Press a button to turn a light on! Use a light sensor to activate an alarm! With the app, students can code the behaviours of blocks in any way they can imagine, enabling them to make anything from simple reactions to complex creations in minutes. Students can use SAM Labs to design, write and debug programs, applying sequencing, selection and iteration. They will use logical reasoning to write algorithms, incorporating variables, inputs and outputs. Using the blocks and app, they will learn to control and simulate physical systems.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. Inivata's innovative approach utilizes TAm-Seq technology to detect and analyze genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples, known as liquid biopsies. This method revolutionizes cancer detection and monitoring by providing a less invasive alternative to traditional biopsies. The company's focus is on enabling clinicians to make more informed treatment decisions by monitoring response to therapies and detecting potential relapses in cancer patients. Inivata has also formed a strategic collaboration with NeoGenomics, Inc.

Silicon Microgravity Limited specializes in the development of advanced sensor devices tailored for the oil and gas sector. Founded in 2014 as a spin-out from Cambridge University, the company leverages sensor technology originally developed through a collaboration with BP. This technology enables the recording of gravity data at high sensitivities and seismic data at ultra-low frequencies, significantly enhancing the management of oil and gas reservoirs. By using microelectromechanical system sensors, Silicon Microgravity transforms the measurement of densities deep within reservoirs from boreholes. Additionally, its technology finds applications in navigation, guidance, and stabilization for various intelligent systems across commercial, industrial, and military sectors. The innovations provided by Silicon Microgravity aim to improve efficiency and reduce costs for clients while supporting their social, safety, and environmental objectives.

Import.io is the number one Web Data Integration provider. Import.io deliver the world’s data directly to enterprises, fueling business insight and competitive advantage. The Import.io Web Data Integration solution extracts, prepares and integrates high-quality comprehensive web data into customers’ analytics platforms and business applications. The company delivers data to more than 850 customers from millions of web sources.

Kesios Therapeutics Limited is a London-based company founded in 2012, focused on developing small molecule drugs for hematological malignancies, particularly multiple myeloma and related conditions. The company is dedicated to creating novel therapeutics that aim to induce normal cell death while simultaneously allowing cancer cells to survive under specific conditions, thereby addressing the unmet medical needs of patients with cancer. Through its innovative approach, Kesios seeks to advance treatment options for individuals battling these challenging diseases.

WaveOptics, Ltd. is a designer and manufacturer of advanced augmented reality display technology, specializing in diffractive waveguides for wearable devices. Founded in 2014 and based in Abingdon-on-Thames, United Kingdom, the company focuses on creating optical components that enhance the augmented reality experience. Their patented technology utilizes waveguide hologram physics and photonic crystals, allowing for lightweight, high field-of-view displays in full RGB color. By employing thin transparent substrates embedded with nanostructures, WaveOptics' devices manipulate light to generate images without the need for bulkier components traditionally used in AR systems. The company has established strategic partnerships with industry leaders such as Compal, Wistron, and Plessey to further its mission in the augmented reality market.

Telectic they provide AI capability to read the web and uncover hard to find B2B prospects, map emerging sectors, segment accounts and monitor companies on particular topics or signals. They have developed a crawler that understands the content from the web, reading company websites, news, social media, academic, official, and other sources.

Puridify conducts research and development activities on bioprocessing technologies aimed at advancing industrial biomolecule manufacture. The company was founded by Tom Haywood, Oliver Hardick, and Iwan Roberts in March 2013 and is based in United Kingdom.

Oxford Biotrans Limited is a company based in Abingdon, United Kingdom, that focuses on the development and commercialization of high-value chemical compounds through enzyme technology. Established in 2013, it leverages patented cytochrome P450 enzyme technology to create products such as Nootkatone, a naturally derived flavor and fragrance from Valencene, a citrus extract. The company aims to introduce innovative enzymatic routes for producing specialty chemicals, with initial offerings centered on flavors and fragrances. Additionally, the technology has broader applications in the production of pheromones, pharmaceuticals, and other specialty chemicals. With over 15 years of research backing its initiatives, Oxford Biotrans is committed to providing environmentally friendly ingredients that minimize chemical waste and energy consumption.

Autifony Therapeutics Limited, a biotechnology company, develops medicines to treat hearing disorders such as hearing loss and tinnitus. The company was incorporated in 2011 and is based in London, United Kingdom.

Abingdon Health is a technology-enabled company specializing in lateral flow diagnostics, focused on developing, manufacturing, and marketing medical diagnostic solutions globally. Founded in 2008 and based in York, United Kingdom, the company offers a range of products, including the AbC-19 Rapid Test for COVID-19 neutralizing antibodies, as well as tests for self-test HIV, equine infections, and human fertility. Abingdon Health also provides services in lateral flow test development, manufacturing, and reader customization. Its business operations are divided into three main segments: Contract Development, which involves development work for third parties; Contract Manufacturing, encompassing both development and manufacturing activities; and Product Sales, which includes sales of various diagnostic products. The majority of the company's revenue is generated from its Contract Development segment.

Auspherix, an Australian early stage anti-infectives company. Auspherix will seek further investment or industry partnerships to move the novel antibiotics into pre-clinical and clinical development, potentially for broad spectrum use.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, founded in 2014. It focuses on the research and development of innovative therapies for respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company aims to create disease-modifying therapies that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increased susceptibility to lung infections. By developing these novel treatments, Enterprise Therapeutics seeks to enhance the quality of life for patients suffering from these chronic respiratory conditions.

Akamis Bio is a clinical-stage oncology company dedicated to improving the lives of cancer patients through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company is focused on developing a range of therapeutics aimed at solid tumors, utilizing its proprietary T-SIGn virus platform administered intravenously. This approach aims to enhance the ability of a patient's immune system to identify, attack, and eliminate cancer cells, providing a targeted treatment option for those affected by cancer.

Yoyo Wallet Limited is a mobile wallet company based in London, United Kingdom, that facilitates customer transactions for retailers, universities, and corporate locations. Founded in 2013 and originally known as JustYoyo Limited, the company rebranded in April 2015. Yoyo Wallet enables users to make payments using their smartphones, processing over 150,000 monthly in-store transactions by integrating payment and loyalty features through a simple scanning process. Additionally, it offers a marketing platform that enhances digital customer engagement for retailers, allowing them to deliver loyalty programs and rewards tailored to individual buying patterns.

Cortexica is a London based, global service provider of practical AI solutions for businesses. Providing clarity and insight from within the noise around AI, Cortexica delivers world-leading Computer Vision image recognition and search technologies supported by industry specific consultancy. Working with clients across a range of verticals including retail, media, manufacturing and pharmaceuticals, Cortexica’s technology is robust and flexible and can be integrated to any requirements on any system or platform, including on device. The ability to partner with clients to create AI solutions for their specific needs, from innovation to delivery, ensures maximum benefit and return on investment. Cortexica was developed from the Bioengineering Department of Imperial College London, and originated from a pioneering research to reverse-engineer the human visual cortex.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

Kuur Therapeutics Limited specializes in the development and commercialization of CAR-NKT cell immunotherapies aimed at treating various forms of cancer. The company has established a pipeline of innovative immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics focuses on creating off-the-shelf engineered CAR-NKT cell therapies, harnessing the unique capabilities of natural killer T cells combined with advanced CAR construct engineering. This approach aims to provide effective treatments for both solid and hematological tumors, thereby enhancing patient care. Established in 2005 and based in London, the company was previously known as Cell Medica Limited before rebranding in February 2020. Kuur Therapeutics is actively engaged in clinical trials to advance its CAR-NKT cell therapies.

Kesios Therapeutics Limited is a London-based company founded in 2012, focused on developing small molecule drugs for hematological malignancies, particularly multiple myeloma and related conditions. The company is dedicated to creating novel therapeutics that aim to induce normal cell death while simultaneously allowing cancer cells to survive under specific conditions, thereby addressing the unmet medical needs of patients with cancer. Through its innovative approach, Kesios seeks to advance treatment options for individuals battling these challenging diseases.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. Inivata's innovative approach utilizes TAm-Seq technology to detect and analyze genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples, known as liquid biopsies. This method revolutionizes cancer detection and monitoring by providing a less invasive alternative to traditional biopsies. The company's focus is on enabling clinicians to make more informed treatment decisions by monitoring response to therapies and detecting potential relapses in cancer patients. Inivata has also formed a strategic collaboration with NeoGenomics, Inc.

Lontra is an engineering and manufacturing company specializing in innovative air and gas compressor technology. The company has developed the Blade Compressor®, an award-winning and patented design that represents a significant advancement in compressor technology, being the first major new design in over 80 years. This compressor is recognized for its efficiency, reportedly achieving up to one-third more energy savings than traditional models while enhancing reliability. Lontra is actively expanding its technology into various industries, including general manufacturing, cement, food and drink, pharmaceuticals, and water treatment. The company has garnered support through numerous grants and awards from organizations such as Innovate UK and the Royal Academy of Engineering, highlighting its commitment to innovation and sustainability. In 2020, Lontra received the IMechE Award for Innovation in Bulk Materials and Handling, underscoring its impact in the engineering field.

Cortexica is a London based, global service provider of practical AI solutions for businesses. Providing clarity and insight from within the noise around AI, Cortexica delivers world-leading Computer Vision image recognition and search technologies supported by industry specific consultancy. Working with clients across a range of verticals including retail, media, manufacturing and pharmaceuticals, Cortexica’s technology is robust and flexible and can be integrated to any requirements on any system or platform, including on device. The ability to partner with clients to create AI solutions for their specific needs, from innovation to delivery, ensures maximum benefit and return on investment. Cortexica was developed from the Bioengineering Department of Imperial College London, and originated from a pioneering research to reverse-engineer the human visual cortex.

Featurespace is a leader in enterprise financial crime prevention, specializing in fraud detection and anti-money laundering solutions. The company has developed innovative technologies, including Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, which are incorporated into its ARIC platform. This real-time machine learning software assesses risk and monitors customer data across more than 180 countries to identify fraudulent activities and suspicious behavior promptly. The ARIC Risk Hub utilizes advanced anomaly detection methods, allowing financial institutions to automatically recognize potential threats and respond to them effectively. Over 30 major global financial institutions, including well-known names such as HSBC and NatWest, leverage Featurespace’s solutions to safeguard their operations and enhance customer satisfaction while minimizing fraud-related costs.

Puridify conducts research and development activities on bioprocessing technologies aimed at advancing industrial biomolecule manufacture. The company was founded by Tom Haywood, Oliver Hardick, and Iwan Roberts in March 2013 and is based in United Kingdom.

Yoyo Wallet Limited is a mobile wallet company based in London, United Kingdom, that facilitates customer transactions for retailers, universities, and corporate locations. Founded in 2013 and originally known as JustYoyo Limited, the company rebranded in April 2015. Yoyo Wallet enables users to make payments using their smartphones, processing over 150,000 monthly in-store transactions by integrating payment and loyalty features through a simple scanning process. Additionally, it offers a marketing platform that enhances digital customer engagement for retailers, allowing them to deliver loyalty programs and rewards tailored to individual buying patterns.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

TopiVert Ltd. is a clinical-stage biotechnology company based in London, United Kingdom, focused on developing narrow spectrum kinase inhibitors as locally-acting treatments for chronic inflammatory diseases affecting the gastrointestinal tract and the eyes. Founded in 2010, the company is advancing its lead program, TOP1288, which is undergoing a Phase IIa proof of concept study for ulcerative colitis. Additionally, TopiVert is preparing to initiate a Phase I/II study for its second program, TOP1630, aimed at addressing dry eye syndrome. The company's innovative approach enables the delivery of medications at pharmacologically relevant concentrations directly to the targeted areas, potentially leading to improved treatment outcomes for patients.

Econic Technologies Ltd. is a UK-based chemical technology company that specializes in developing innovative processes for producing polymers and polyurethanes using carbon dioxide and epoxides. Founded in 2011 and located in Macclesfield, the company focuses on transforming waste CO2 into valuable materials through advanced catalyst chemistry. Its product offerings include polycarbonates and polycarbonate polyols, which find applications in various sectors such as mattresses, home insulation, footwear, packaging, and construction. The company’s technology not only reduces dependence on fossil fuels but also aims to provide environmental benefits by mitigating greenhouse gas emissions. With a team of skilled scientists and engineers operating from a state-of-the-art facility at Alderley Park, Econic Technologies is committed to advancing sustainable practices in the plastics industry while fostering economic growth.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

Plaxica Limited is a technology and licensing company that specializes in the production of biopolymers and platform chemicals derived from renewable resources. Founded in 2008 and based in the United Kingdom, Plaxica develops innovative products such as Optipure® D Lactic Acid, Xylex® Lignin Free Sugars, and Versalac® Low Cost Lactic Acid technology. Its biopolymers, including polylactic acid, are utilized across various industries, including food packaging, automotive, textiles, electronics, and household goods. By focusing on sustainable materials, Plaxica aims to contribute to environmentally friendly solutions in multiple sectors.

Yoyo Wallet Limited is a mobile wallet company based in London, United Kingdom, that facilitates customer transactions for retailers, universities, and corporate locations. Founded in 2013 and originally known as JustYoyo Limited, the company rebranded in April 2015. Yoyo Wallet enables users to make payments using their smartphones, processing over 150,000 monthly in-store transactions by integrating payment and loyalty features through a simple scanning process. Additionally, it offers a marketing platform that enhances digital customer engagement for retailers, allowing them to deliver loyalty programs and rewards tailored to individual buying patterns.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

Cambridge Communication Systems Limited, based in Cambridge, United Kingdom, specializes in designing and developing self-organizing wireless backhaul solutions. Founded in 2010, the company focuses on providing cost-effective connectivity for various applications, including small cells, Wi-Fi, CCTV, and smart city infrastructure. Its flagship product, Metnet, features self-organizing 5G microwave backhauls and is complemented by the Metnet SON Multipoint solution, which operates in the 24/26/28GHz frequency range. The company's technology enables intelligent, self-optimizing, and self-healing mesh networks, allowing network operators to extend fiber connectivity effectively. This approach facilitates the development of hybrid fiber-wireless networks that cater to diverse environments, from urban to rural areas, and supports a wide range of users from residential to enterprise settings.

Impression Technologies offer a fully tailored service according to your engineering needs from concept to production. We provide the knowledge and expertise to support HFQ® technology, empowering you to transform your project. Our facility, located in Coventry, UK, is fully equipped to carry out in-house prototyping and production runs to support our HFQ customers and partners.

Semetric was founded in 2008 by Gregory Mead, Marie-Alicia Chang and Matthew Jeffery. The Chief Technical Officer, Jameel Syed, was a founding member of life sciences data and business analytics company InforSense. Its Executive Chairman, Dr Jeremy Silver, was previously Chief Executive of Sibelius Software and Vice President, new media at EMI Group in Los Angeles. Executive Vice President, Musicmetric North America, Daniel Savage was previously General Manager of Maverick records and has held positions at Atlantic, Island, and Hollywood Records.

Musicmetric offers detailed analytics and trend forecasting for the music industry. Musicmetric is creating software tools and services using machine learning algorithms designed to measure online buzz and deliver relevant analytics. Their tools enable deep analysis of marketing performance, designed to add efficiency and accurate campaign targeting. Additionally, their software offers predictive trend forecasting for artists, genres and sales within the mainstream label, indie and unsigned sectors of the music industry. The company processes terabytes of raw text daily and performs data mining and classification analysis to generate the data which powers its software products. It is also releasing a suite of free widgets powered by the data generated in the back end, as well as opening an API to allow third parties to build applications on top of the musicmetric data. The customer base includes labels, A&R, managers, promoters and marketing agencies.

Acunu Analytics specializes in providing a platform for low-latency, continuous analytics on big data, enabling real-time insights across various industries such as manufacturing, telecommunications, media, and financial services. The company's offerings include dashboards and embedded applications designed for monitoring and controlling complex environments where high-velocity data is prevalent. Central to Acunu's technology is the Cassandra NoSQL database, and the company actively contributes to its development by sharing innovations with the wider community. Founded in 2009 by a team of researchers and engineers from Cambridge and Oxford, Acunu operates offices in London and California, and is supported by prominent venture capital firms in Europe.

Kuur Therapeutics Limited specializes in the development and commercialization of CAR-NKT cell immunotherapies aimed at treating various forms of cancer. The company has established a pipeline of innovative immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics focuses on creating off-the-shelf engineered CAR-NKT cell therapies, harnessing the unique capabilities of natural killer T cells combined with advanced CAR construct engineering. This approach aims to provide effective treatments for both solid and hematological tumors, thereby enhancing patient care. Established in 2005 and based in London, the company was previously known as Cell Medica Limited before rebranding in February 2020. Kuur Therapeutics is actively engaged in clinical trials to advance its CAR-NKT cell therapies.

Akamis Bio is a clinical-stage oncology company dedicated to improving the lives of cancer patients through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company is focused on developing a range of therapeutics aimed at solid tumors, utilizing its proprietary T-SIGn virus platform administered intravenously. This approach aims to enhance the ability of a patient's immune system to identify, attack, and eliminate cancer cells, providing a targeted treatment option for those affected by cancer.

Oxford Immunotec is a medical diagnostics company specializing in the development of novel tests for various diseases through its patented T cell measurement technology. The company has pioneered the T-SPOT.TB test, an interferon gamma release assay designed to diagnose latent tuberculosis infection and active TB disease, serving as a modern alternative to the traditional Mantoux skin test. In addition to its focus on tuberculosis, Oxford Immunotec is dedicated to advancing proprietary diagnostic tests for a range of underserved immune-regulated conditions, including chronic infections, transplantation, autoimmune and inflammatory diseases, and immune oncology. Through its innovative approach, the company aims to enhance the management of these conditions and improve patient outcomes.

Featurespace is a leader in enterprise financial crime prevention, specializing in fraud detection and anti-money laundering solutions. The company has developed innovative technologies, including Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, which are incorporated into its ARIC platform. This real-time machine learning software assesses risk and monitors customer data across more than 180 countries to identify fraudulent activities and suspicious behavior promptly. The ARIC Risk Hub utilizes advanced anomaly detection methods, allowing financial institutions to automatically recognize potential threats and respond to them effectively. Over 30 major global financial institutions, including well-known names such as HSBC and NatWest, leverage Featurespace’s solutions to safeguard their operations and enhance customer satisfaction while minimizing fraud-related costs.

Abingdon Health is a technology-enabled company specializing in lateral flow diagnostics, focused on developing, manufacturing, and marketing medical diagnostic solutions globally. Founded in 2008 and based in York, United Kingdom, the company offers a range of products, including the AbC-19 Rapid Test for COVID-19 neutralizing antibodies, as well as tests for self-test HIV, equine infections, and human fertility. Abingdon Health also provides services in lateral flow test development, manufacturing, and reader customization. Its business operations are divided into three main segments: Contract Development, which involves development work for third parties; Contract Manufacturing, encompassing both development and manufacturing activities; and Product Sales, which includes sales of various diagnostic products. The majority of the company's revenue is generated from its Contract Development segment.

Econic Technologies Ltd. is a UK-based chemical technology company that specializes in developing innovative processes for producing polymers and polyurethanes using carbon dioxide and epoxides. Founded in 2011 and located in Macclesfield, the company focuses on transforming waste CO2 into valuable materials through advanced catalyst chemistry. Its product offerings include polycarbonates and polycarbonate polyols, which find applications in various sectors such as mattresses, home insulation, footwear, packaging, and construction. The company’s technology not only reduces dependence on fossil fuels but also aims to provide environmental benefits by mitigating greenhouse gas emissions. With a team of skilled scientists and engineers operating from a state-of-the-art facility at Alderley Park, Econic Technologies is committed to advancing sustainable practices in the plastics industry while fostering economic growth.

Cambridge Communication Systems Limited, based in Cambridge, United Kingdom, specializes in designing and developing self-organizing wireless backhaul solutions. Founded in 2010, the company focuses on providing cost-effective connectivity for various applications, including small cells, Wi-Fi, CCTV, and smart city infrastructure. Its flagship product, Metnet, features self-organizing 5G microwave backhauls and is complemented by the Metnet SON Multipoint solution, which operates in the 24/26/28GHz frequency range. The company's technology enables intelligent, self-optimizing, and self-healing mesh networks, allowing network operators to extend fiber connectivity effectively. This approach facilitates the development of hybrid fiber-wireless networks that cater to diverse environments, from urban to rural areas, and supports a wide range of users from residential to enterprise settings.

Epsilon-3 Bio Ltd. is a preclinical stage company with investment from Index Ventures, Novo Ventures and Imperial Innovations. The company is focused on the efficient development of first in class drug candidates stimulating safe removal of cellular debris. Such agents are expected to provide a useful treatment for a wide range of diseases including inflammation and autoimmunity, neurodegeneration, fibrosis and cancer.

TopiVert Ltd. is a clinical-stage biotechnology company based in London, United Kingdom, focused on developing narrow spectrum kinase inhibitors as locally-acting treatments for chronic inflammatory diseases affecting the gastrointestinal tract and the eyes. Founded in 2010, the company is advancing its lead program, TOP1288, which is undergoing a Phase IIa proof of concept study for ulcerative colitis. Additionally, TopiVert is preparing to initiate a Phase I/II study for its second program, TOP1630, aimed at addressing dry eye syndrome. The company's innovative approach enables the delivery of medications at pharmacologically relevant concentrations directly to the targeted areas, potentially leading to improved treatment outcomes for patients.

Chirp is dedicated to simplifying connectivity through the use of sound. The company has developed machine-to-machine communication software that allows devices equipped with loudspeakers or microphones to exchange data via inaudible sound waves. This innovative approach is supported by extensive research and a skilled engineering team, enabling the seamless interconnection of millions of devices in a scalable and cost-effective manner. By enhancing the end-user experience and adding value to existing hardware, Chirp positions itself as a leader in sound-based data transmission technology.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

Plaxica Limited is a technology and licensing company that specializes in the production of biopolymers and platform chemicals derived from renewable resources. Founded in 2008 and based in the United Kingdom, Plaxica develops innovative products such as Optipure® D Lactic Acid, Xylex® Lignin Free Sugars, and Versalac® Low Cost Lactic Acid technology. Its biopolymers, including polylactic acid, are utilized across various industries, including food packaging, automotive, textiles, electronics, and household goods. By focusing on sustainable materials, Plaxica aims to contribute to environmentally friendly solutions in multiple sectors.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Autifony Therapeutics Limited, a biotechnology company, develops medicines to treat hearing disorders such as hearing loss and tinnitus. The company was incorporated in 2011 and is based in London, United Kingdom.

Nexeon Limited is a developer and manufacturer of advanced silicon-based anode materials for rechargeable lithium-ion batteries. Founded in 2006 and headquartered in Abingdon, United Kingdom, with an additional office in Yokohama, Japan, the company focuses on creating innovative battery materials that enhance energy density and capacity. These improvements allow for the production of lighter, more powerful batteries that can support a variety of applications, including consumer electronics, electric vehicles, sustainable energy, aerospace, medical, and defense industries. By enabling longer battery life and faster charging times, Nexeon's technology plays a crucial role in advancing sustainable energy solutions and supporting the transition to a net-zero environment. The company boasts a skilled technical team with diverse expertise to drive its research and development efforts.

Stanmore Implants is an established orthopaedic company specializing in the design and manufacture of bespoke and modular implants for limb-sparing procedures, as well as complex primary and revision joint replacements. The company offers a custom implant service and maintains a diverse portfolio of orthopaedic implants recognized for their effectiveness in limb salvage and joint replacement. In addition to traditional implant solutions, Stanmore has developed ITAP technology, which facilitates the attachment of prosthetics to the skeleton of amputees. The company expanded its capabilities by acquiring robotic bone preparation technology through the purchase of Acrobot, a firm focused on computer-assisted orthopaedic surgery, in 2010. Founded in 1948 and headquartered in London, Stanmore Implants was acquired by Stryker in 2016, enhancing its position in the orthopaedic market.

Novacem Limited, based in London, UK, specializes in the development of innovative cement solutions that leverage magnesium oxide. The company's primary focus is on creating carbon-negative cement systems that have the potential to significantly reduce the environmental impact of the cement industry, traditionally known for its high carbon dioxide emissions. By utilizing magnesium oxide and hydrated magnesium carbonates, Novacem aims to transform cement production into a process that can absorb CO2, thereby contributing to more sustainable construction practices and addressing climate change challenges.

A spin-out from Imperial Innovations plc and headquartered within the Imperial College Incubator, RepRegen is poised to commercialize the initial product of its hard tissue repair and regeneration platform: StronBoneâ„¢ Bone Graft Substitute. The Company's hard tissue platform is based on 'smart' bioceramics designed to be used, initially, by orthopedic product manufacturers and surgeons. A major RepRegen materials science innovation is the use of Strontium, boosting the performance of the bioceramics.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

Akamis Bio is a clinical-stage oncology company dedicated to improving the lives of cancer patients through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company is focused on developing a range of therapeutics aimed at solid tumors, utilizing its proprietary T-SIGn virus platform administered intravenously. This approach aims to enhance the ability of a patient's immune system to identify, attack, and eliminate cancer cells, providing a targeted treatment option for those affected by cancer.

BioCeramic Therapeutics Ltd. develops medical interventions that enable the body to renew damaged tissues. It offers products to help patients suffering from a range of bone and soft tissue related conditions. BioCeramic Therapeutics Ltd. was formerly known as Advanced Tissue Therapies Ltd. and changed its name to BioCeramic Therapeutics Ltd. in 2007. The company was incorporated in 2006 and is based in London, the United Kingdom.

Plaxica Limited is a technology and licensing company that specializes in the production of biopolymers and platform chemicals derived from renewable resources. Founded in 2008 and based in the United Kingdom, Plaxica develops innovative products such as Optipure® D Lactic Acid, Xylex® Lignin Free Sugars, and Versalac® Low Cost Lactic Acid technology. Its biopolymers, including polylactic acid, are utilized across various industries, including food packaging, automotive, textiles, electronics, and household goods. By focusing on sustainable materials, Plaxica aims to contribute to environmentally friendly solutions in multiple sectors.

Kuur Therapeutics Limited specializes in the development and commercialization of CAR-NKT cell immunotherapies aimed at treating various forms of cancer. The company has established a pipeline of innovative immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics focuses on creating off-the-shelf engineered CAR-NKT cell therapies, harnessing the unique capabilities of natural killer T cells combined with advanced CAR construct engineering. This approach aims to provide effective treatments for both solid and hematological tumors, thereby enhancing patient care. Established in 2005 and based in London, the company was previously known as Cell Medica Limited before rebranding in February 2020. Kuur Therapeutics is actively engaged in clinical trials to advance its CAR-NKT cell therapies.

Novacem Limited, based in London, UK, specializes in the development of innovative cement solutions that leverage magnesium oxide. The company's primary focus is on creating carbon-negative cement systems that have the potential to significantly reduce the environmental impact of the cement industry, traditionally known for its high carbon dioxide emissions. By utilizing magnesium oxide and hydrated magnesium carbonates, Novacem aims to transform cement production into a process that can absorb CO2, thereby contributing to more sustainable construction practices and addressing climate change challenges.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

Evince Technology is a UK-based start-up focused on developing innovative electron devices for various industries, including metrology, healthcare, communications, and advanced manufacturing. The company has created a new type of solid-state switch that aims to transform the high-frequency electronics sector. Its technology leverages synthetic diamonds to enhance the performance of these devices through thermionic valves, which utilize the exceptional thermal and electronic properties of diamonds. This advancement positions Evince as a key player in providing efficient solutions for effective electrical energy control, catering to the needs of developers and manufacturing partners.

Spiral Gateway is a fabless semiconductor chip vendor with products that are designed to enhance flexibility and performance in the Image Signal Processing (ISP) market. The company was formed in 2004 as a spinout from the University of Edinburgh and holds exclusive rights to RICA (Reconfigurable Instruction Cell Architecture), a novel processing architecture and associated tool chain. This technology has the potential to achieve cost & performance points for existing signal processing functions, directly comparable with fixed function custom hardware, whilst offering the significant additional benefit of high degrees of flexibility through software programmability.

Molecular Vision is an optical detection company that offers a platform technology solution for versatile optical detection in a portable format. It carries an integration of low-cost organic light emitting diodes and organic photodetectors with analytical devices. This enables the realization of hand-held disposable medical diagnostics devices for point-of-care testing. Additional applications for the portable quantitative analytical devices include in-the-field veterinary testing, food and plant testing, environmental monitoring, and homeland security. Molecular Vision was founded in 2001 and is based in London, United Kingdom.

NanoBioDesign Limited (NBD) was formed in 2001 and is a spinout company from Imperial College London. The company has acquired the exclusive rights to four patents emanating from the research of Professor Gianfranco Gilardi and his group. Professor Gilardi has been active in the field of biological sensor research for 10 years, focussing upon human and bacterial P450’s.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

Southside Thermal Sciences is developing an integrated system for turbine engines consisting of thermal barrier coatings (TBC) and the instruments required to make use of them. The TBC technology, which is patent-protected in the USA and Europe, has been developed for use on high temperature turbine blades, as used in gas-turbine power generators and aircraft engines. When illuminated by UV light the coatings provide accurate temperature readings leading to savings in operating costs and greater efficiency.

InforSense, Ltd. provides enterprise business intelligence and reporting software. Its products include core technology, such as InforSense Platform that enables organizations to integrate, automate, and visualize data sources, information, and analysis processes to deliver predictive insights. Its core technology products also include VisualSense, advanced analytics, reporting, TextSense, document explore, automation, workflow library, In-Oracle edition, Siebel edition, and virtual machine. The company also provides Life Science Applications products, such as ClinicalSense, a clinical research software application for cohort identification for clinical researchers; GenSense that enables the analysis of data from the latest generation of high-throughput genotyping platforms; Translational Research solution that provides a framework to integrate and analyze clinical, patient specimen, and experimental data for clinical translational research; BioSense that provides an interactive analytics environment for designing and executing bioinformatics solutions ranging from sequence analysis to microarray informatics and remote database annotation; and ChemSense that provides a vendor-neutral environment for designing and executing cheminformatics solutions. In addition, it offers business intelligence products and solutions, such as asset management, credit risk, CRM analytics, operational risk, and Siebel edition datasheet solutions. Further, the company provides consulting, workshop, and training services. The company serves pharmaceutical, biotechnology, consumer goods, healthcare, financial services, manufacturing, and communications companies. It has operations in the United Kingdom, the United States, Germany, and Japan. InforSense, Ltd. was founded in 1999 and is based in London, the United Kingdom with additional offices in Cambridge, Massachusetts; and Shanghai, China. As of June 2009, InforSense Ltd. operates as a subsidiary of ID Business Solutions Ltd.

Lontra is an engineering and manufacturing company specializing in innovative air and gas compressor technology. The company has developed the Blade Compressor®, an award-winning and patented design that represents a significant advancement in compressor technology, being the first major new design in over 80 years. This compressor is recognized for its efficiency, reportedly achieving up to one-third more energy savings than traditional models while enhancing reliability. Lontra is actively expanding its technology into various industries, including general manufacturing, cement, food and drink, pharmaceuticals, and water treatment. The company has garnered support through numerous grants and awards from organizations such as Innovate UK and the Royal Academy of Engineering, highlighting its commitment to innovation and sustainability. In 2020, Lontra received the IMechE Award for Innovation in Bulk Materials and Handling, underscoring its impact in the engineering field.

Midaz Lasers manufactures high power diode-pumped solid state laser products for micromachining applications.

Veryan Medical Ltd. specializes in the design and development of innovative vascular biomimetic stent technology. Founded in 2003 as a spin-out from Imperial College London, the company has created the BioMimics 3D stent, which utilizes a unique three-dimensional helical geometry to mimic natural blood vessel structure. This design enhances blood flow mechanics, promoting secondary swirling flow and increasing wall shear stress, which protects the endothelium and improves patient outcomes in treating symptomatic peripheral arterial disease. Veryan Medical is headquartered in Horsham, United Kingdom, with a research and development facility located in Galway, Ireland. The company operates as a subsidiary of Otsuka Medical Devices Co., Ltd. as of December 2018.

StyleCaster is a digital media and technology platform that provides its users with fashion trend reports, shopping guides, and celebrity style news. It enables women to share their style statements through its platform. The platform works with various brands to create a better advertising approach as well as to engage with women who care about the way they look and feel. It was launched in 2008 by Ari S. Goldberg, Maverick Carter, David A. Goldberg, Albert Azout, Brandon Perlman, and Doug Imbruce.

Pointshare is a national leader in connecting local healthcare communities with secure, online business services that enhance communication, create efficiencies, and improve the delivery of care. Pointshare is the only company that has developed the technology, infrastructure, and hands-on service to create a proven, practical solution for automating the day-to-day business transactions of healthcare.